Hikma completes acquisition of Ben Venue manufacturing site
Will transfer equipment to other plants within the US and Europe
Hikma Pharmaceuticals has completed its acquisition of substantially all of the assets of the generic injectables manufacturing site of Ben Venue Laboratories, part of the Boehringer Ingelheim Group, as agreed on 24 July.
The Ben Venue site includes four manufacturing plants and a Quality and Development Centre, containing a R&D pilot plant, and will significantly strengthen Hikma's R&D capabilities and support the development of a strong future pipeline, the company said.
All manufacturing at the Ben Venue site ceased in December 2013 after Boehringer Ingelheim said the costs involved in solving quality issues were unsustainable. Hikma will transfer some of the equipment at the site to increase capacity at its other manufacturing plants in the US and Europe.